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ABSTRACT
Purpose. This study was designed to determine (1) rates
of clinically meaningful tumor reduction in breast tumor
size following neoadjuvant chemotherapy (NAC), (2)
which receptor subtypes and MRI phenotypes are associ-
ated with clinically meaningful tumor reduction, and (3)
whether MRI phenotype impacts concordance between
pathologic and MRI size.
Methods. We analyzed data from the I-SPY TRIAL, a
multicenter, prospective NAC trial. Reduction in tumor
size from [4 to B4 cm was considered clinically mean-
ingful, as crossing this threshold was considered a
reasonable cutoff for potential breast conservation therapy
(BCT). MRI phenotypes were scored between one (well-
defined) and five (diffuse) on pre-NAC MRIs.
Results. Of 174 patients with tumors [4 cm, 141 (81 %)
had clinically meaningful tumor reduction. Response to
therapy varied by MRI phenotype (p = 0.003), with well-
defined phenotypes more likely than diffuse phenotypes to
have clinically meaningful tumor shrinkage (91 vs. 72 %,
p = 0.037). Her2? and triple-negative (Tneg) tumors had
the highest rate of clinically meaningful tumor reduction
(p = 0.005). The concordance between tumor diameter on
MRI and surgical pathology was highest for Her2? and
Tneg tumors, especially among tumors with solid imaging
phenotypes (p = 0.004).
Discussion. NAC allows most patients with large breast
tumors to have clinically meaningful tumor reduction,
meaning response that would impact ability to undergo BCT.
However, response varies by imaging and tumor subtypes.
Concordance between tumor size on MRI and surgical
pathology was higher in well-defined tumors, especially
those with a Tneg subtype, and lower in HR? diffuse tumors.
Neoadjuvant chemotherapy (NAC) is used increasingly
for breast cancer treatment, with two main benefits: it
offers the ability to monitor response to treatment, where
pathologic complete response (pCR) is prognostic, and it
can result in downstaging of tumor and breast conservation
treatment (BCT) or eliminate the need for postmastectomy
radiation in the setting of pCR.1–6 Many factors influence
the choice of surgical procedure after NAC: patient pref-
erence, tumor appearance, hormone receptor (HR) and
Her2 expression status, and treatment response.7,8 Whereas
the post-NAC MRI often is used to determine whether
BCT is possible, investigators note that the pre-NAC MRI
influences surgeons’ recommendations, regardless of tumor
appearance after NAC.9 Because clinicians and patients
seek to avoid reexcision, it is important to understand the
reliability of the postchemotherapy MRI.10–13
Physical examination, ultrasound, and mammography
have only moderate accuracy in predicting residual disease,
whereas MRI longest diameter and volumetric measurements
are the most accurate measures after chemotherapy.14–17
Despite this, both false positives and negatives remain. A
better understanding of imaging reliability and which features
predict successful BCT could affect surgical
management.18,19
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We previously identified that MRI phenotypes (solid
and well-contained vs. diffuse and infiltrative) correspond
with degree of response to NAC and predict the ability to
achieve breast conservation.20 In this study, we investi-
gated whether MRI phenotype and receptor subtype
predicted rates of clinically meaningful tumor reduction in
a larger cohort with imaging and molecular data. Surgeon
comfort with attempting BCT varies and was not man-
dated; our primary endpoint therefore was crossing the
threshold from [4 cm to tumor size of B4 cm, a reason-
able cutoff for potential BCT. We also investigated
whether the correlation between tumor size on post-NAC




Patients received anthracycline-based chemotherapy,
followed by a taxane regimen on the I-SPY 1 TRIAL
(CALGB 150007/150012, ACRIN 6657).1,2 Herceptin was
used neoadjuvantly in Her2? patients after 2005. This
study was approved by the UCSF institutional review
board.
MRI Technique
Contrast-enhanced MRI was performed on 1.5T MRI
scanners using dedicated breast radiofrequency coils
(details previously described).21 Unilateral images were
acquired using 3D, fat-suppressed, T1-weighted spoiled
gradient echo (SPGR) imaging with spatial resolution
B1 mm/pixel in-plane and B2.5-mm slice thickness. Pre-
and postgadolinium (0.1 mmol/kg) imaging was performed
at prespecified temporal resolution to achieve imaging at
*2.5 and 7.5 min after contrast administration. Tumors
were assigned one of five MRI phenotypes based on pre-
NAC imaging: 1—well defined, unicentric mass; 2—well
defined, multilobulated mass; 3—area enhancement with
nodularity; 4—area enhancement without nodularity; 5—
septal spreading (Fig. 1). Pre-NAC MRI phenotype was
determined by a centrally trained breast radiologist at each
study site.
Determination of Tumor Marker Subtypes
Core biopsies were obtained at each site before NAC,
and immunohistochemical and genomic markers were
performed as previously described.1,2
Postsurgical Pathology Analysis
Seven study pathologists were trained on evaluation of
gross and microscopic sections using a standardized tool:
the residual cancer burden method.22 Training was done by
Dr. Fraser Symmans, who reviewed the first five cases from
each pathologist. An electronic tool was built to capture
extent of disease. Pathology size was re-reviewed and
longest diameter from this central re-review was used as
the largest size.
Definition of Clinically Meaningful Tumor Reduction
Subjects were considered potentially eligible for BCT
before receiving NAC if the tumor was B4 cm on both pre-
NAC clinical examination and pre-NAC MRI. This cut
point was chosen based on its use in the National Surgical
Adjuvant Breast and Bowel Project B-06.23 Patients with
tumors[4 cm in size before NAC were considered to have
a clinically meaningful tumor reduction if the tumor was
B4 cm on surgical pathology. Discrepancy between post-
NAC MRI and surgical pathology was defined as a dif-
ference in longest tumor diameter of C2 cm (cutoff based
FIG. 1 Examples of each of the five MRI phenotypes: 1 well defined, unicentric mass; 2 well defined, multilobulated mass; 3 area enhancement
with nodularity; 4 area enhancement without nodularity; 5 septal spreading
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on internal consensus). Employment of stricter cutoffs (up
to 1.5 cm) did not significantly alter our findings.
Statistical Analysis
As most variables were not normally distributed, median
values and ranges are reported. The Kruskal–Wallis test
was used to compare continuous variables, and contin-
gency tables with the v2 test were used for categorical
variables.24 MRI phenotypes were analyzed as five distinct
categories, as well by dichotomization into well-defined
versus diffuse categories. p values were two-sided, and




Of the 221 subjects in the I-SPY TRIAL, 198 had data
available for pre- and posttreatment MRIs, pretreatment
clinical examinations, type of surgery, and surgical
pathology; 193 had pre-NAC HR and Her2 status avail-
able.1,2 Of the 198 subjects in this study, 24 had tumors
B4 cm on both pre-NAC clinical examination and pre-
NAC MRI.
Clinically Meaningful Tumor Reduction
Of the 174 subjects with tumors [4 cm on pre-NAC
clinical examination and MRI, 141 (81 %) had a clinically
meaningful tumor reduction after NAC based on a tumor
size B4 cm on surgical pathology. Sixty-one of these 174
(35 %) subjects received BCT. Of the 141 subjects whose
tumors shrank to B4 cm, 52 (37 %) received BCT, 2
(1.4 %) had attempted BCT but subsequently required
mastectomy for positive margins, and 87 (62 %) underwent
mastectomy. The most common reasons for not receiving
BCT included multicentric disease (22 %) and patient
choice (22 %; Supplementary Table 1).
The response to NAC varied by MRI phenotype
(p = 0.037). Patients with well-defined pre-NAC MRI
phenotypes (Fig. 1) had higher rates of clinically mean-
ingful tumor reduction than those with diffuse phenotypes
(92 vs. 72 %; Fig. 2a). The rates of BCT were higher in the
well-defined phenotypes compared with the diffuse phe-
notypes (47 vs. 27 %, p = 0.023; Fig. 2a).
The rate of clinically meaningful tumor reduction also
varied by receptor subtype (p = 0.005). Her2? and Tneg
(HR-/Her2-) tumors had higher rates compared with the
HR?/Her2- group (Fig. 2b). However, there was no sig-
nificant difference in BCT rates (Fig. 2b). Analysis using a
3-cm cutoff for clinically meaningful tumor reduction
yielded similar results.
MRI/Pathology Concordance
Pretreatment tumor size varied by MRI phenotype pat-
tern (p = 0.002; Supplementary Table 2). In addition,
tumor diameter on pre-NAC MRI differed significantly
from tumor diameter by palpation (paired Wilcoxon rank-
sum test, p = 0.01) and this difference varied by imaging
a b
FIG. 2 a Bar plot showing percentage of patients who had clinically
meaningful tumor reduction (blue) and who received BCT (yellow)
after NAC by MRI phenotype; pink line represents the average rate of
clinically meaningful tumor reduction (81 %). Subjects with well-
defined MRI phenotypes (1 and 2) were more likely to have a
clinically meaningful tumor reduction and receive BCT after NAC.
b Bar plot showing same data by receptor subtype. Her2? and Tneg
tumors had a higher likelihood of having clinically meaningful tumor
reduction after NAC compared to HR?/Her2- tumors; however, the
actual rates of receiving BCT do not differ by subtype
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phenotype (p = 0.003) with a median size difference of
-0.4, -0.2, 0.9, 0.65, and 2 cm for phenotypes 1–5,
respectively. Clinical diameter tended to be larger than
MRI diameter in solid tumors. In diffuse phenotypes, the
MRI size was larger than by clinical exam (Fig. 3). One
Tneg tumor was excluded from this analysis because the
tumor took up the entire breast, so preoperative size was
not recorded.
The post-NAC MRI longest diameter measurements
differed from diameter measured on surgical pathology
(Fig. 4). Of the 198 subjects analyzed, 75 (38 %) had a
discrepancy of C2 cm between size on imaging and
pathology. Of the 75 discrepant cases, the tumor size on
post-NAC MRI was greater than pathology in 52 cases
(69 %) and smaller in 23 cases (31 %). There were 18
cases (9 %) in which pathology showed no tumor, but post-
NAC MRI tumor size was C2 cm, and 7 cases (3.5 %) in
which post-NAC MRI showed no tumor, but pathology
showed C2 cm of tumor. MRI/pathology concordance
varied by tumor subtype (p = 0.004), with size discrep-
ancies present in half of all HR?/Her2- tumors but lower
discrepancy rates in Her2? and Tneg tumors. Underesti-
mation of disease by[2 cm was rare (4.3 %) in solid MRI
tumor patterns. In cases where the post-NAC MRI under-
estimated the tumor size, all tumors were either diffuse
and/or HR?/Her2- or Her2?, and none were Tneg.
Within each marker subtype, diffuse tumors were more
likely to have size discrepancies. Overall, diffuse HR?
Her2- tumors were most likely to have discrepancies
between post-NAC MRI and surgical pathology (Fig. 4).
Similar trends were observed among patients who received
BCT (80/198 total patients analyzed), with the highest
discrepancy rates in HR? HER2- diffuse cases (31 vs.
19 % all others) and MRI underestimation of tumor size
occurring only in diffuse and/or HR? cases. Additionally,
employing stricter cutoffs for discrepancy (up to 1.5 cm)
did not alter these findings.
FIG. 3 Vertical axis shows the difference in centimeters between
tumor diameter on pre-NAC MRI and tumor diameter palpated on
pre-NAC physical examination. Horizontal axis shows results by MRI
phenotype. Overall, palpation underestimated tumor size in the
diffuse tumors and slightly overestimated in solid tumors. Note that
one Tneg case was left out of this analysis
FIG. 4 Vertical axis shows the
difference in centimeters between post-
NAC MRI longest diameter and tumor
size on surgical pathology. Solid tumors
had smaller size discrepancies than
diffuse tumors. MRI underestimated
path tumor size only in diffuse or HR?
tumors. For cases where MRI was
accurate (\2 cm difference), there were
72 solid and 51 diffuse cases. For cases
were MRI overestimated path tumor
size, there were 16 solid and 36 diffuse
cases. MRI most often overestimated
the size of diffuse tumors, except in the
case of HR?/Her2- tumors. Circles
represent MRI phenotypes 1 and 2;
Triangles are phenotypes 3, 4, and 5
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MRI Phenotype and Tumor Subtype
The most common patterns were MRI phenotypes 2 and
3 (Table 1). There were significant differences in the
receptor subtype distribution for well-defined versus dif-
fuse MRI categories (p = 0.015 by v2 test). The Tneg
(HR-/Her2-) group made up a larger proportion of the
well-defined MRI phenotypes (35 %) than the diffuse
phenotypes (15 %). The diffuse patterns had a higher
proportion of HR? cases (68 %) than the well-defined
patterns (52 %; Fig. 5). However, all phenotypes were
represented in each receptor subtype.
DISCUSSION
Overall, the results in this prospective cohort of patients
confirm our previous findings that tumor morphology,
captured by MRI phenotype, and tumor subtype affect rates
of achieving clinically meaningful tumor reduction after
NAC.26 Patients with well-defined MRI phenotypes and
those with Her2? and Tneg tumors were more likely to
have tumor shrinkage to B4 cm. We and others have found
an improved correlation between post-NAC MRI and sur-
gical pathology in tumors that are well-defined by
imaging.27 Together, these findings suggest that MRI
phenotype may be used in conjunction with tumor subtype
to set appropriate expectations before undergoing NAC.
MRI phenotype and tumor subtype likely reflect bio-
logical differences between tumors. Other phenotypic
features are associated with different tumor subtypes.
Basal-like breast tumors have distinct histologic and im-
munotypic properties, with characteristics, such as central
scar, tumor necrosis, spindle cells, squamous metaplasia,
high mitotic count, and high nuclear to cytoplasmic
ratio.28,29 Most of these Tneg tumors have mass-like
imaging patterns on MRI.30,31 Even on mammogram and
ultrasound, breast cancer subtypes have imaging charac-
teristics, with Tneg cancers more likely to have smooth
margins.32,33
MRI phenotype and marker status influenced the like-
lihood of size discrepancies between imaging and
pathology. Similarly, Chen et al.9,34 found that MRI was
less accurate in tumors that present as non-mass enhance-
ment on MRI, and in another study suggest that MRI can be
used more successfully to plan BCT in Her2? patients.
Others also have reported that post-NAC MRI appears to
be less accurate in ER? tumors and most accurate in Tneg
or Her2? tumors and that pre-NAC tumor size and
response also impact accuracy.34–37 Although some have
reported the highest accuracy of MRI for Her2- disease,
not knowing HR status and differences in rates of tra-
ztuzumab use could potentially account for the disparate
results.38 Benign proliferative processes can enhance on
TABLE 1 Patient and tumor characteristics: age, stage, histology,
grade, chemotherapeutic regimens, HR/Her2 marker status, surgical
treatment received, and MRI phenotype
Total (n = 198)
Number (%)










Mixed ductal-lobular 7 (3.5)







Doxorubicin (A)/cyclophosphamide (C) 9 (4.6)














Lumpectomy followed by mastectomy 2 (1)
Mastectomy 116 (59)
MRI Phenotype
1 well defined unicentric mass 33 (16.7 %)
2 well defined multilobulated mass 59 (29.8 %)
3 area enhancement with nodularity 60 (30.3 %)
4 area enhancement without nodularity 28 (14.1 %)
5 septal spreading 18 (9.1 %)
Potentially Eligible for BCT
Pre-NAC (palpation and MRI \4 cm)
Yes 24 (14 %)
No 150 (86 %)
Post-NAC (pathology size \4 cm)
Yes 141 (81 %)
No 33 (19 %)
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MRI and are difficult to differentiate from low-grade, ER?
DCIS lesions. False-positive MRI enhancement may reflect
a spectrum of change within high-risk tissue, possibly
explaining why it is difficult to distinguish residual tumor
size in ER-positive patients, especially with diffuse
disease.39,40
We previously reported differences in response to NAC
based on the five MRI phenotypes described. Patients with
well-circumscribed masses had the greatest response to
NAC.20 In the current study, the majority of patients
(81 %) achieved shrinkage to tumor size B4 cm, whereas
we previously found only 47 % achieved enough shrinkage
to be potentially eligible for BCT.26 This was likely due to
the addition of taxane, which doubles the pCR rate com-
pared with doxorubicin alone.41 For tumor subtypes,
adjusting for pre-NAC tumor size did not change our
results. For MRI phenotype, we found that size and phe-
notype were associated, because diffuse tumors will
necessarily occupy a larger space. The larger size of these
diffuse tumors could influence the ability to reach the
threshold of B4 cm, but separating the contribution of
phenotype from size is not possible in this study. The tumor
response to NAC also can affect MRI accuracy, with good
correlation between MRI and pathology noted in tumors
with extreme responses (either complete or none), and
worse correlation among partial responders.42,43
For the MRI phenotypes, the well-defined groups had
higher BCT rates, but no difference was seen among tumor
subtypes. Whereas patient choice was a factor in 22 % of
cases that were potentially candidates for but did not receive
BCT, other factors, such as physician recommendations,
could play a role in surgical decisions. Knowing the accu-
racy of MRI could alter these recommendations.
Interestingly, post-NAC MRI longest diameter showed a
stronger association with surgical procedure than tumor size
on surgical pathology or post-NAC mammographic longest
diameter among the 175 patients assessed by all three
methods (Wilcoxon rank-sum test, p = 0.001, 0.17, and
0.02 respectively). There was no significant difference in
local recurrence or recurrence free survival between subjects
who received BCT and those who received mastectomy.44
More than one third of patients had a size discrepancy
C2 cm between the post-NAC MRI and surgical pathol-
ogy. Some have suggested that overestimation on MRI
could be a result of taxane causing increased vascular
permeability and gadolinium uptake, or related to an
inflammatory infiltrate or necrosis.43,45 We found more
discrepancies in the diffuse tumor phenotypes, which likely
reflects increased difficulty in measuring tumor diameter.
These discrepancies were particularly notable in the diffuse
HR?/Her2- tumors and make it more difficult to set
expectations based on post-NAC MRI in these tumor types.
However, in the setting of HR- tumors of solid pheno-
types, post-NAC imaging did not underestimate residual
tumor size. When MRI showed a pCR, the surgical
pathology was concordant.
The strengths of this study include central assessment of
HR/Her2 status and the consistent timing of MRIs. There
were dedicated breast radiologists at each site who under-
went centralized training to validate the MR phenotypes.
Size assessment can be somewhat subjective, however,
especially for diffuse tumors. Adding tumor volume mea-
surements may help to decrease the chance of
overestimating the tumor size compared to surgical
pathology. Despite these limitations, however, the findings
are consistent with those reported in the literature, with the
additional finding that MRI size estimates are less likely to
correspond well with pathology for HR? diffuse tumors.
These findings have clinical implications. Whereas the
majority did not attain a pCR, most patients attained clin-
ically meaningful tumor reduction. The MRI phenotype
and tumor subtype can inform the discussion about the
likelihood of achieving enough response to be potentially
eligible for BCT. Whether this information would increase
rates of receiving BCT is unknown, but increased under-
standing, particularly of the accuracy of post-NAC MRI,
could impact recommendations and patient decisions.
Overall, many more patients have clinically meaningful
tumor reductions than have a pCR. Although the reasons
for not receiving BCT are complex, there is likely room for
improvement in offering BCT to more patients. We are
currently developing an algorithm based on biologic and
MRI features to help determine the chances of having a
clinically meaningful tumor reduction and the likely
FIG. 5 Whereas the relative proportions of tumor subtypes varied
between the well-defined and diffuse MRI phenotypes, both groups
contained all four receptor based subtypes
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accuracy of MR post-NAC to guide this decision-making
process.
ACKNOWLEDGMENT The research for Alliance (CALGB)
150007 and 150012 was supported, in part, by grants from the National
Cancer Institute (CA31946) to the Alliance for Clinical Trials in
Oncology (Monica M. Bertagnolli, M.D., Chair) and to the Alliance
Statistical Center (Daniel J. Sargent, Ph.D., CA33601). Additional
funding includes: National Cancer Institute Specialized Program of
Research Excellence in Breast Cancer (CA58207), American College
of Radiology Imaging Network (CA079778 & CA080098), National
Cancer Institute Center for Bioinformatics, The Breast Cancer
Research Foundation, and Bruce and Martha Atwater. The content of
this manuscript is solely the responsibility of the authors and does not
necessarily represent the official views of the National Cancer Insti-
tute. Dr. Mukhtar received support from the California Breast Cancer
Research Program (Post-doctoral fellowship 15FB-0108).
OPEN ACCESS This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
REFERENCES
1. Esserman LJ, et al. Chemotherapy response and recurrence-free
survival in neoadjuvant breast cancer depends on biomarker pro-
files: results from the I-SPY 1 TRIAL (CALGB 150007/150012;
ACRIN 6657). Breast Cancer Res Treat. 2012;132:1049–62.
2. Esserman LJ, et al. Pathologic complete response predicts
recurrence-free survival more effectively by cancer subset: results
from the I-SPY 1 TRIAL–CALGB 150007/150012, ACRIN
6657. J Clin Oncol. 2012;30:3242–9.
3. Fisher B, et al. Effect of preoperative chemotherapy on the out-
come of women with operable breast cancer. J Clin Oncol.
1998;16(8):2672–85.
4. Wolmark N, et al. Preoperative chemotherapy in patients with
operable breast cancer: nine-year results from National Surgical
Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst
Monogr. 2001;30:96–102.
5. Rastogi P, et al. Preoperative chemotherapy: updates of National
Surgical Adjuvant Breast and Bowel Project Protocols B-18 and
B-27. J Clin Oncol. 2008;26(5):778–85.
6. Hortobagyi GN, et al. Multimodal treatment of locoregionally
advanced breast cancer. Cancer. 1983;51(5):763–8.
7. Shenoy HG, et al. Practical advice on clinical decision making
during neoadjuvant chemotherapy for primary breast cancer. Surg
Oncol. 2009;18(1):65–71.
8. Caldon LJ, Walters SJ, Reed MW. Changing trends in the deci-
sion-making preferences of women with early breast cancer. Br J
Surg. 2008;95(3):312–8.
9. Chen JH, et al. Impact of MRI-evaluated neoadjuvant chemo-
therapy response on change of surgical recommendation in breast
cancer. Ann Surg. 2009;249(3):448–54.
10. Morrow M. Magnetic resonance imaging for screening, diagno-
sis, and eligibility for breast-conserving surgery: promises and
pitfalls. Surg Oncol Clin N Am. 2010;19(3):475–92.
11. Morrow M. Magnetic resonance imaging in the preoperative
evaluation of breast cancer: primum non nocere. J Am Coll Surg.
2004;198(2):240–1.
12. Houssami N, et al. Accuracy and surgical impact of magnetic
resonance imaging in breast cancer staging: systematic review
and meta-analysis in detection of multifocal and multicentric
cancer. J Clin Oncol. 2008;26(19):3248–58.
13. Kwong MS, et al. Postchemotherapy MRI overestimates residual
disease compared with histopathology in responders to neoadju-
vant therapy for locally advanced breast cancer. Cancer J.
2006;12(3):212–21.
14. Chagpar AB, et al. Accuracy of physical examination, ultraso-
nography, and mammography in predicting residual pathologic
tumor size in patients treated with neoadjuvant chemotherapy.
Ann Surg. 2006;243(2):257–64.
15. Bhattacharyya M, et al. Using MRI to plan breast-conserving
surgery following neoadjuvant chemotherapy for early breast
cancer. Br J Cancer. 2008;98(2):289–93.
16. McLaughlin R, Hylton N. MRI in breast cancer therapy moni-
toring. NMR Biomed. 2011;24(6):712–20.
17. Lorenzon M, et al. Assessment of breast cancer response to
neoadjuvant chemotherapy: is volumetric MRI a reliable tool?
Eur J Radiol. 2009;71(1):82–8.
18. Stucky CC, et al. Does magnetic resonance imaging accurately
predict residual disease in breast cancer? Am J Surg. 2009;198(4):
547–52.
19. Lee JM, et al. MRI before reexcision surgery in patients with
breast cancer. AJR Am J Roentgenol. 2004;182(2):473–80.
20. Esserman L, et al. MRI phenotype is associated with response to
doxorubicin and cyclophosphamide neoadjuvant chemotherapy in
stage III breast cancer. Ann Surg Oncol. 2001;8(6):549–59.
21. Hylton NM, et al. Locally advanced breast cancer: MR imaging for
prediction of response to neoadjuvant chemotherapy results from
ACRIN 6657/I-SPY TRIAL. Radiology. 2012;263(3):663–672.
22. Symmans WF, et al. Measurement of residual breast cancer burden
to predict survival after neoadjuvant chemotherapy. J Clin Oncol.
2007;25(28):4414–22.
23. Fisher B, et al. Twenty-year follow-up of a randomized trial
comparing total mastectomy, lumpectomy, and lumpectomy plus
irradiation for the treatment of invasive breast cancer. N Engl J
Med. 2002;347(16):1233–41.
24. Kruskal WH, Wallis WA. Citation classic: use of ranks in one-cri-
terion variance analysis. Curr Contents Arts Humanit. 1987(40):20.
25. Pearson K. On the theory of contingency and its relation to
association and normal correlation. London: Dulau and Co.;
1904. p 35.
26. Gomez R, et al. Preliminary results from I-SPY trial: tumor
patterns on pre-treatment MRI predict breast conservation ther-
apy eligibility. In: San Antonio Breast Cancer Symposium 2007:
San Antonio, TX.
27. McGuire KP, et al. MRI staging after neoadjuvant chemotherapy
for breast cancer: does tumor biology affect accuracy? Ann Surg
Oncol. 2011;18(11):3149–54.
28. Livasy CA, et al. Phenotypic evaluation of the basal-like subtype
of invasive breast carcinoma. Mod Pathol. 2006;19(2):264–71.
29. Fulford LG, et al. Specific morphological features predictive for
the basal phenotype in grade 3 invasive ductal carcinoma of
breast. Histopathology. 2006;49(1):22–34.
30. Chen JH, et al. Triple-negative breast cancer: MRI features in 29
patients. Ann Oncol. 2007;18(12):2042–3.
31. Uematsu T, Kasami M, Yuen S. Triple-negative breast cancer:
correlation between MR imaging and pathologic findings. Radi-
ology. 2009;250(3):638–47.
32. Wang Y, et al. Estrogen receptor-negative invasive breast cancer:
imaging features of tumors with and without human epidermal
growth factor receptor type 2 overexpression. Radiology.
2008;246(2):367–75.
33. Wang X, et al. The mammographic correlations with basal-like
phenotype of invasive breast cancer. Acad Radiol. 2010;17(3):
333–9.
MRI Phenotype and Tumor Subtype 3829
34. Chen JH, et al. MRI evaluation of pathologically complete
response and residual tumors in breast cancer after neoadjuvant
chemotherapy. Cancer. 2008;112(1):17–26.
35. Straver ME, et al. MRI-model to guide the surgical treatment in
breast cancer patients after neoadjuvant chemotherapy. Ann Surg.
2010;251(4):701–7.
36. Loo CE, et al. Magnetic resonance imaging response monitoring
of breast cancer during neoadjuvant chemotherapy: relevance of
breast cancer subtype. J Clin Oncol. 2011;29(6):660–6.
37. Nakahara H, et al. MR and US imaging for breast cancer patients
who underwent conservation surgery after neoadjuvant chemo-
therapy: comparison of triple negative breast cancer and other
intrinsic subtypes. Breast Cancer. 2010;18(3):152–60.
38. Moon HG, et al. Age and HER2 expression status affect MRI
accuracy in predicting residual tumor extent after neo-adjuvant
systemic treatment. Ann Oncol. 2009;20(4):636–41.
39. Esserman LJ, et al. Magnetic resonance imaging captures the
biology of ductal carcinoma in situ. J Clin Oncol. 2006;24(28):
4603–10.
40. Kumar AS, et al. Biologic significance of false-positive magnetic
resonance imaging enhancement in the setting of ductal carci-
noma in situ. Am J Surg. 2006;192(4):520–4.
41. Mamounas EP. NSABP Protocol B-27. Preoperative doxorubicin
plus cyclophosphamide followed by preoperative or postoperative
docetaxel. Oncology (Williston Park). 1997;11(6 Suppl 6):37–40.
42. Fangberget A, et al. Neoadjuvant chemotherapy in breast cancer-
response evaluation and prediction of response to treatment using
dynamic contrast-enhanced and diffusion-weighted MR imaging.
Eur Radiol. 2011;21(6):1188–99.
43. Wasser K, et al. Accuracy of tumor size measurement in breast
cancer using MRI is influenced by histological regression induced
by neoadjuvant chemotherapy. Eur Radiol. 2003;13(6):1213–23.
44. Alvarado M, et al. Predictors of local recurrence in high-risk patients
undergoing neoadjuvant chemotherapy in the ISPY trial. In: San
Antonio Breast Cancer Symposium. 2010. San Antonio, TX.
45. Kim HJ, et al. Accuracy of MRI for estimating residual tumor
size after neoadjuvant chemotherapy in locally advanced breast
cancer: relation to response patterns on MRI. Acta Oncol.
2007;46(7):996–1003.
3830 R. A. Mukhtar et al.
